Introduction
Cardiac biomarkers are integral to the diagnosis and the treatment of acutely ill cardiac patients. The Working Group on Acute Cardiac Care of the European Society of Cardiology has established a Study Group to deal with issues related to cardiac biomarkers in this important area. Biomarkers are used to augment physician skill and judgment. Accordingly, we will outline principles for the application of biomarkers in acute cardiac care in a series of consensus documents; the first was on cardiac troponin (cTn). 1 The present review is on natriuretic peptides (NPs) as markers of cardiac stress and heart failure (HF). Natriuretic peptides help diagnostically and provide prognostic information. Most data have been obtained with assays measuring B-type natriuretic peptide (BNP) or N-terminal proB-type natriuretic peptide (NT-proBNP); therefore, the review focuses on these two markers, and it will mention new markers at the end. 2, 3 Pathophysiology and biochemistry of natriuretic peptides
The endocrine nature of the heart was first understood with the description of atrial natriuretic peptide (ANP), 4 and later detection of brain (B-type) natriuretic peptide, that is, BNP, 5, 6 which is mainly released from the myocardium in humans. 7 B-type natriuretic peptide has similar biological effects to ANP. Both are produced primarily in the atria under normal conditions. 8 Atrial natriuretic peptide is mostly stored in atrial granules and thus available for ready release; BNP is stored to a limited extent. B-type natriuretic peptide requires de novo synthesis to be released in substantial amounts but the BNP gene responds rapidly. 9 The atria contain the highest BNP and ANP concentrations in normals but this is shifted to the ventricles for BNP in HF. 10 Natriuretic peptides promote natriuresis and diuresis, vasodilation, and antagonize the effects of the renin -angiotensin -aldosterone and sympathetic nervous systems (see Table 1 ). 11 In the central nervous system, NPs act as neurotransmitters and decrease sympathetic tone, reduce secretion of arginine-vasopressin and corticotrophin, and inhibit salt appetite and water drinking. 12 Natriuretic peptides modulate myocardial and vascular structure and function via antiproliferative and cytoprotective effects. 9, 11, 13 Of the three known membrane bound natriuretic peptide receptors (NPRs), the guanylyl cyclase -coupled NPR -A and NPR -B receptors are responsible for most biological effects. Natriuretic peptide receptor-C is responsible for clearance and possibly regulation of cell proliferation. B-type natriuretic peptide exerts its activities via binding to NPR-A mediated by its second messenger, cyclic guanosine monophosphate, which regulates ion channels, protein kinases, and phosphodiesterases.
In response to cardiac pathologies with pressure or volume overload, ventricular myocytes re-express foetal genes including ANP and BNP. Then, most of the BNP is released from the ventricles. 8 NPs are increased in all oedematous disorders with salt and fluid overload and those with increased atrial or ventricular wall tension, e.g. in HF and renal failure 9 ( Table 2) . Natriuretic peptides are quantitative markers related to the extent of left ventricular † This document was approved by the Nucleus of the ESC Working Group on Acute Cardiac Care in August 2010.
(LV) dysfunction and the severity of HF, although there is considerable overlap across functional classes. The predominant stimulus for release of BNP is end-diastolic wall stress. 9,14 -19 However, BNP is also increased in patients with atrial fibrillation due to atrial distension. In addition, myocardial ischaemia evokes BNP secretion, 19, 20 as do paracrine factors, such as angiotensin II, endothelin, and cytokines. 13 B-type natriuretic peptide can also be secreted from myocardial fibroblasts.
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Biochemistry of proB-type natriuretic peptide-derived peptides
Our understanding of the biochemistry of BNP, its processing, and circulating proBNP-derived peptides is incomplete. 14 The gene for BNP encodes a 134-amino acid preproBNP precursor. Removal of a 26-amino acid signal peptide gives rise to a 108-amino acid proBNP. 15 Fragments of this signal peptide are present in blood of normals and patients with acute myocardial infarction (AMI).
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ProB-type natriuretic peptide is cleaved into BNP 1-32 and NT-proBNP 1-76 mainly upon secretion although some processed BNP is found in cardiomyocytes. Endoproteases and prohormone convertases, such as furin and corin, are involved in proBNP processing. 16 -18 B-type natriuretic peptide exhibits biological activity, but NT-proBNP has no and proBNP has little. 23 There are only small amounts of intact BNP 
Critical clinical concepts
(1) Natriuretic peptides are secreted from the heart in response to cardiac haemodynamic stress mediated by volume and/or pressure overload. (2) Natriuretic peptides are semi-quantitative markers of cardiac stress and HF, and thus related to the extent of atrial, ventricular, and valvular dysfunction. (3) Natriuretic peptides are neither HF nor heart disease specific. (4) Heart Failure is characterized by a dysfunctional natriuretic peptide system. Relatively inactive proB-type natriuretic peptide is the major circulating form. 32 and the National Academy of Biochemistry (NACB) and C-SMCD. 33 Clinicians must know how to prepare for blood sampling, how the sample is collected, and some of the analytical fundamentals for proper test interpretation. These are partly method dependent and must be established for each commercially available assay separately. Since there is predominantly one source of antibodies and calibrators for NT-proBNP assays (Roche w ), NT-proBNP sample stability is similar for NT-proBNP assays. N-terminal proB-type natriuretic peptide is stable at room temperature for at least 2 days. 34 The long-term stability of frozen samples is at least 4 months at 2208C and at least 1 year at 2808C. 35, 36 The in vitro stability of BNP is assay dependent.
Values are stable for at least 4 h at room temperature. There are conflicting reports on the long-term stability of frozen samples and thus must be reported by assay manufacturers. Instability of ethylene diamine tetra acetic (EDTA) plasma samples with high BNP concentrations has been reported even at 2808C. 37 In order to be safe, a protease inhibitor cocktail including kallikrein-and serine-specific protease inhibitors should be added. 32 In acute cardiac care situations, blood sampling conditions are less important. N-terminal proB-type natriuretic peptide still is more stable than BNP. 38 For BNP, EDTA whole blood or plasma collected in plastic tubes is the only acceptable specimens. They should be analysed as soon as possible. In vitro stability depends on the assay. 39 For NT-proBNP, serum or heparin plasma is specimens of choice. N-terminal proB-type natriuretic peptide is stable during storage, either glass or plastic tubes are acceptable. Ethylene diamine tetra acetic acid plasma gives a negative bias of 8-10% compared with serum. 34 Current available assays are not standardized, which means that results are not comparable in a given patient. Further, BNP and NT-proBNP values in a given sample may differ between assays using the same antibodies due to matrix effects.
N-terminal proB-type natriuretic peptide assays
Antibodies and calibrator materials used in routine assays are listed in Table 3 (adapted from http://www.ifcc.org/pdf/scientificactivities/ committees/c-smcd/np_assay_tablev091209.pdf). Assay harmonization is incomplete probably due to matrix effects. 39 -41 N-terminal proB-type natriuretic peptide assays concur in classifying patients as having values below or above 125 ng/L, which was the initially proposed cut-off. With all assays a value of 300 ng/L works well for exclusion of acute HF. However, NT-proBNP assays may have a systematic bias at higher concentrations. 39, 40 Many manufacturers have switched or are going to switch to monoclonal antibodies. These assays provide almost identical results to polyclonal assays. 42 
B-type natriuretic peptide assays
There are at least four different antibodies in various combinations and diverse calibrators using recombinant or synthetic BNP 1-32 for BNP assays (see Table 4 , adapted from http://www.ifcc.org/pdf/ scientificactivities/committees/c-smcd/np_assay_tablev091209.pdf). Thus, there are substantial differences between methods. 39, 41 Even assays using the same antibodies run on different instruments vary markedly. In general, there is good concurrence around values of 100 ng/L, which is the initially proposed cut-off. That value excludes acute HF with high negative predictive value.
Detection and reference limits
Since NPs manifest high biological variability, analytical sensitivity, and precision are not as critical as for cTn assays. B-type natriuretic peptide and NT-proBNP assays should have a total coefficient of variation of ≤15% at concentrations corresponding to age and gender defined upper reference limits (URL function, a normal haemoglobin, and a normal body mass index (BMI). 43 -45 Values often are greatly increased in the acute setting, so a smaller number of decision levels adjusted for age, gender, and renal function can be used to exclude acute HF.
Serial measurements
Changes over time depend on biological and analytical variability. 46, 47 Although NT-proBNP has somewhat lower individual variation, intra-individual biological variability ( 30-50%) for all NPs is greater than analytical imprecision. 48 Therefore, changes must be large to be important (.40-50%). 46, 49 Only marked deviations from baseline (NT-proBNP .50% and BNP .60%) correlated with haemodynamic improvement in acute HF. 50 Hence, frequent blood sampling is unnecessary. Laboratories should report reference change values based on published biological variation and analytical imprecision. A practical approach is to consider only changes .30% as clinically relevant.
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Clinical use of B-type natriuretic peptide and N-terminal proB-type natriuretic peptide
There are no differences in the diagnostic use of BNP and NT-proBNP except when using nesiritide. B-type natriuretic peptide and NT-proBNP correlate well but NT-proBNP concentrations are higher. B-type natriuretic peptide and NT-proBNP results must be interpreted in the context of the clinical situation and should be used as continuous variables. The higher the NP level, the higher the likelihood of HF. However; applying a solitary decision limit for all situations is imprudent. Absolute levels are not interchangeable between assays.
Clinical implications of natriuretic peptide testing in acute heart failure
Identifying HF is challenging, especially in the emergency department (ED The International Collaborative for NT-proBNP Study (ICON) established cut-points for NT-proBNP (Figure 2 ). An age-independent cut-point of 300 ng/L had 98% negative predictive value for ruling out HF. Age-related cut-points of 450, 900, and 1800 ng/L for ages ,50, 50-75, and .75 years are used to rule-in HF with normal or mildly impaired renal function. 55 Obese patients with HF have lower levels. This may be due to a defect in NP secretion or clearance receptors in adipose tissue. Although, NT-proBNP falls below the cut-points less often, both markers have reduced sensitivity with severe obesity. 63 Performance of NPs is maximized as continuous variables in patients with an intermediate pre-test probability. 64 Thus, routine use in low-and high-risk groups is controversial. The strongest evidence for NPs in HF is their high negative predictive value. Natriuretic peptides cannot be used to distinguish diastolic from systolic HF although values tend to be lower with diastolic HF. There are few situations where NPs are not elevated despite acute haemodynamic compromise and/or severe acute pulmonary congestion. These occur when patients present within the first hour of the onset of pulmonary oedema caused by acute mitral regurgitation because of the need for de novo synthesis of NPs, those with preserved ejection fractions and those with constrictive pericarditis without intrinsic heart disease.
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Natriuretic peptide testing in patients with acute dyspnoea
The economic benefits in ED patients have been studied. 68 -71 Natriuretic peptides result in more rapid initiation of therapy, a reduction in intensive care use, a reduction in the duration of hospitalization, and costs. 68 These findings were partly confirmed in the Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) study using NT-proBNP. Duration of ED visits, readmissions, and medical costs were reduced by better diagnosis. 69 However, these results were not confirmed in a study using BNP 70 or in another with NT-proBNP. The duration of ED stay was unchanged although there was a reduction in the duration of hospitalizations. 71 These moderate results suggest using NPs as an aid to diagnose ED patients, particularly in those at intermediate probability.
Risk stratification in patients with acute heart failure Natriuretic peptide measurements on admission or during hospitalization are useful for risk stratification irrespective of the cause. 55,72 -77 Natriuretic peptide concentrations help quantify the severity of HF and to predict short-and long-term mortality. An admission NT-proBNP concentration .5180 ng/L is strongly predictive of death by 76 days. 55 The value with the best balance of sensitivity and specificity for 1-year mortality was .986 ng/ L. 74 Changes during hospitalization are useful for risk stratification and independent predictors of death or hospital readmission. A predischarge NT-proBNP concentration .4137 ng/L portends a poor prognosis. 75 Similar findings were observed with smaller relative changes in BNP, which were associated with worse outcomes. A high predischarge BNP measurement was an independent marker of death or re-admission, 76 and early treatment lowering BNP level by 30% was associated with improved survival. 77 Treatment guidance in acute heart failure There are no randomized trials using NP guidance in acute HF. B-type natriuretic peptide-guided therapy may reduce all-cause mortality in patients with chronic HF, especially in patients ,75 years. 78, 79 Other studies mainly reported an increased survival free of hospitalization with this approach. 80 It is reasonable to collect a baseline sample and a second prior to discharge for risk assessment. Patients are at lower risk with reductions .30%. These measurements identify those in need of more aggressive management. 81 Natriuretic peptides in acute pulmonary embolism
Increased levels identify patients with acute pulmonary embolism (PE) at higher risk. In patients with raised NP values, elevated troponins are an independent prognostic marker. 82 Admission concentrations of NT-proBNP ,500, 600, or 1000 ng/L, respectively, predict better clinical courses. 82 -85 Recommendations for the use of NPs in acute cardiac care
Natriuretic peptides in acute coronary syndrome peptide .210 ng/L at 24 h after admission is the most significant indicator of increased mortality. 98 An NT-pro-BNP concentration on admission also has prognostic value and thus might facilitate the triage of ICU patients.
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Conclusions and outlook
B-type natriuretic peptide and NT-proBNP are markers of cardiac stress but are not cardiac-specific. B-type natriuretic peptide and NT-proBNP have comparable clinical utility, and both help in excluding acute HF. Their use prior to discharge in hospitalized patients aids risk stratification. There is increasing evidence for risk stratification in acute PE and ACS patients. The lower the value, the lower is the risk. A variety of new assays, e.g. mid-regional proANP and proBNP are being developed. So far, these assays are equivalent but no better than other testing.
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